Close

TP53

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

TP53 is a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. TP53 responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in TP53 are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome.
  • CAR Vector Products

  • TCR Cell Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-YJ321 Anti-TP53 (Bp53-11) h(41BB-CD3ζ) CAR, pCDCAR1 Human Bp53-11 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ322 Anti-TP53 (DO-1) h(41BB-CD3ζ) CAR, pCDCAR1 Human DO-1 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ323 Anti-TP53 (DO-7) h(41BB-CD3ζ) CAR, pCDCAR1 Human DO-7 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ324 Anti-TP53 (IMD-53) h(41BB-CD3ζ) CAR, pCDCAR1 Human IMD-53 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ325 Anti-TP53 (SP5) h(41BB-CD3ζ) CAR, pCDCAR1 Human SP5 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ326 Anti-Tp53 (TRP/816) h(41BB-CD3ζ) CAR, pCDCAR1 Human TRP/816 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ327 Anti-TP53 (2F7) h(41BB-CD3ζ) CAR, pCDCAR1 Human, Monkey 2F7 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ328 Anti-TP53 (3A6) h(41BB-CD3ζ) CAR, pCDCAR1 Human, Monkey 3A6 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ821 Anti-TP53 (Bp53-11) h(CD28-CD3ζ) CAR, pCDCAR1 Human Bp53-11 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ822 Anti-TP53 (DO-1) h(CD28-CD3ζ) CAR, pCDCAR1 Human DO-1 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ823 Anti-TP53 (DO-7) h(CD28-CD3ζ) CAR, pCDCAR1 Human DO-7 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ824 Anti-TP53 (IMD-53) h(CD28-CD3ζ) CAR, pCDCAR1 Human IMD-53 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ825 Anti-TP53 (SP5) h(CD28-CD3ζ) CAR, pCDCAR1 Human SP5 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ826 Anti-Tp53 (TRP/816) h(CD28-CD3ζ) CAR, pCDCAR1 Human TRP/816 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ827 Anti-TP53 (2F7) h(CD28-CD3ζ) CAR, pCDCAR1 Human, Monkey 2F7 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ828 Anti-TP53 (3A6) h(CD28-CD3ζ) CAR, pCDCAR1 Human, Monkey 3A6 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.